Calls for papers
-
Maryland-based CRO Next Breath, which specializes in OINDP analysis, has announced that an October 15, 2012 GMP inspection by the FDA found the company’s Baltimore facility to be compliant. The inspection resulted in no Form… Read more . . .
-
OINDP component manufacturer Presspart has announced the appointment of Ameet Sule as Director of its new Inhalation Product Technology Centre (IPTC) in Blackburn, UK. Sule, who was most recently Director of Pulmonary Research at Lupin,… Read more . . .
-
Fortical salmon calcitonin nasal spray manufacturer Unigene says that it is in danger of running out of cash before the end of the first quarter of 2013, due in part to the EMA’s July 2012… Read more . . .
-
A study by scientists from the UK Defence Science and Technology Laboratory (Dstl) showed that a single dose of Aradigm’s Lipoquin liposomal ciprofloxacin administered through the nose fully protected mice exposed to an aerosolized “lethal… Read more . . .
-
Aptar Pharma has announced the appointment of Jean-Marc Pardonge as President of Aptar Pharma’s Prescription Division, succeeding Salim Haffar, and as General Manager of Aptar Stelmi. Aptar’s prescription division develops and manufactures a range of… Read more . . .
-
Vienna, Austria-based Marinomed has announced the granting of Chinese patent No. CN101678040, titled “Antiviral Polymer,” for a component of its Mavirex technology platform. According to the company, the patent covers prevention and treatment of the… Read more . . .
-
Copley Scientific has officially launched the SCP5 Super Capacity Pump which is capable of generating flow rates as high as 100 L/min for cascade impaction of dry powder inhalers. The new model, a 1.5 kW… Read more . . .
-
OptiNose has announced Phase 3 results from a study of its sumatriptan nasal powder for the treatment of migraine, as well as a grant from the Research Council of Norway to study nasal delivery of… Read more . . .
-
Pearl Therapeutics has raised $65 million from current investors to enable initiation of Phase 3 trials for its PT003 glycopyrrolate (GP)/formoterol fumarate (FF) MDI for the treatment of COPD, the company says. This round of… Read more . . .
-
According to Savara Pharmaceuticals, the company’s AeroVanc inhaled vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients has been granted orphan drug status by the FDA. Aerovanc inhalation powder, which… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan